This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2024 Nov;397(11):9205-9206.

doi: 10.1007/s00210-024-03348-5.

Correction: Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells

Ege Arzuk¹, Derviş Birim², Güliz Armağan²

Affiliations

Affiliations

¹ Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Ege University, Bornova, 35040, Izmir, Turkey. ege.arzuk@ege.edu.tr.
² Department of Biochemistry, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey.

PMID: 39105800
PMCID: PMC11522160
DOI: 10.1007/s00210-024-03348-5

Published Erratum

Correction: Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells

Ege Arzuk et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov.

. 2024 Nov;397(11):9205-9206.

doi: 10.1007/s00210-024-03348-5.

Authors

Ege Arzuk¹, Derviş Birim², Güliz Armağan²

Affiliations

¹ Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Ege University, Bornova, 35040, Izmir, Turkey. ege.arzuk@ege.edu.tr.
² Department of Biochemistry, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey.

PMID: 39105800
PMCID: PMC11522160
DOI: 10.1007/s00210-024-03348-5

No abstract available

PubMed Disclaimer

Figures

Fig. 2 — Fig. 2
Celecoxib and nimesulide inhibit the colony formation ability of MDAMB-231 cells. Cells were treated with each drug at three dose levels (IC₂₅, IC₅₀, and IC₇₅) for 14 days. Following the treatment period, colonies were stained by 1.25% crystal violet. NIM, nimesulide; CXB, celecoxib. The number of surviving colonies was expressed as a percentage of the control (0.1% DMSO). Values were expressed as mean ± S.D. ***p < 0.0001 (vs. control group)

See this image and copyright information in PMC

Erratum for

Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells.
Arzuk E, Birim D, Armağan G. Arzuk E, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):9191-9202. doi: 10.1007/s00210-024-03286-2. Epub 2024 Jul 11. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38990306 Free PMC article.

Similar articles

Celecoxib inhibits NLRP1 inflammasome pathway in MDA-MB-231 Cells.
Arzuk E, Birim D, Armağan G. Arzuk E, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):9191-9202. doi: 10.1007/s00210-024-03286-2. Epub 2024 Jul 11. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38990306 Free PMC article.
Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
Sugimoto T, Bartholomeusz C, Tari AM, Ueno NT. Sugimoto T, et al. Breast Cancer Res. 2007;9(4):R41. doi: 10.1186/bcr1739. Breast Cancer Res. 2007. PMID: 17612393 Free PMC article.
Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Basu GD, et al. Breast Cancer Res. 2005;7(4):R422-35. doi: 10.1186/bcr1019. Epub 2005 Apr 4. Breast Cancer Res. 2005. PMID: 15987447 Free PMC article.
The NLRP1 Inflammasome in Human Skin and Beyond.
Fenini G, Karakaya T, Hennig P, Di Filippo M, Beer HD. Fenini G, et al. Int J Mol Sci. 2020 Jul 6;21(13):4788. doi: 10.3390/ijms21134788. Int J Mol Sci. 2020. PMID: 32640751 Free PMC article. Review.
To protect or adversely affect? The dichotomous role of the NLRP1 inflammasome in human disease.
Tupik JD, Nagai-Singer MA, Allen IC. Tupik JD, et al. Mol Aspects Med. 2020 Dec;76:100858. doi: 10.1016/j.mam.2020.100858. Epub 2020 Apr 28. Mol Aspects Med. 2020. PMID: 32359693 Review.

See all similar articles

Cited by

Targeting inflammasomes as an immunotherapeutic strategy for cancer.
Huang L, Chen X, Liu R, Nan D, Bao W, Yang L, Dai X, Tang J, Zhang H, Lu Y. Huang L, et al. J Transl Med. 2025 Jun 8;23(1):634. doi: 10.1186/s12967-025-06665-2. J Transl Med. 2025. PMID: 40484954 Free PMC article. Review.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- PubMed Central
- Springer
Miscellaneous
- NCI CPTAC Assay Portal